Illumina (ILMN)
(Delayed Data from NSDQ)
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.
Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.
Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
CBM vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ILMN: Which Stock Is the Better Value Option?
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
by Zacks Equity Research
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
Luminex (LMNX) Misses on Earnings in Q2, Margins Contract
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.
Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates
by Zacks Equity Research
Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.
Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y
by Zacks Equity Research
Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
by Zacks Equity Research
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.